ACTIVE INNOVATION PIPELINE

The Swiss-Swedish collaboration targets a critical immunological mechanism in the advancement of Guillain-Barré Syndrome (GBS) treatment, leveraging unique molecules from PRONOXIS company. This project endeavors to introduce novel drug candidates, employing a groundbreaking immunological mechanism, into clinical trials for GBS. Neurix's contribution lies in providing human in vitro neural tissues to expedite drug development and assess the neurotoxicity of newly developed interventions, specifically Reactive Oxygen Species (ROS) Activators.

Multiple sclerosis (MS) poses a significant neurological disability challenge among young adults, arising from an autoimmune response against myelin and neurodegeneration. A dynamic consortium, comprising universities and companies spanning 11 European countries and the US, is determined to join forces and customize therapies tailored to individual MS patients within an ambitious 5-year timeframe. At Neurix, our mission is to forge ahead with a cutting-edge 3D human in vitro model, revolutionizing the testing of novel MS therapeutic interventions. Focused on the demands of the industry, our aim is to target neurorepair and myelin restoration, taking bold strides towards a brighter future for those affected by this complex neurological condition.

Unraveling Alzheimer's Disease: A Global Pursuit" Understanding the development of Alzheimer's disease (AD) challenges researchers and society, with aging populations in developed countries. Our Swiss-South Korean joint project, "Alzheimer's Kit&Screen," aims to develop a novel diagnostic kit and drug screening assays within 3 years. Utilizing newly identified biomarkers, we'll create human in vitro neural models of AD in 3D (AD mini-brains) to meet industry needs. Validating the drug screening potential of these models is our mission. Together, we revolutionize AD research.

Through complementary expertise from French and Swiss partners, the CELESTE consortium strives to accelerate the development of new immunotherapeutics for Chronic Septic Granulomatosis disease. The innovative approach centers around modeling inflammatory disease through the establishment of cutting-edge in vitro screening tests based on patient-derived human induced pluripotent stem cells (iPSCs). Neurix plays a pivotal role by conducting a comprehensive quality control of iPSCs-derived human hematopoietic stem cells from patients, assessing their potential to differentiate into various blood cell types. This vital evaluation will be instrumental in testing new interventions and therapeutic applications that impact their differentiation potential.